FTSE Russell’s preliminary additions list includes Hyperfine (HYPR) as a health care company expected to enter the Russell 3000 Index through the June 2026 reconstitution. The index changes are scheduled to take effect after U.S. equity markets close on June 26.
Hyperfine said the Russell 3000 inclusion would also place the company in the small-cap Russell 2000 Index and relevant growth and value style indexes. Under the semi-annual schedule beginning in 2026, Russell 3000 membership remains in place for 6 months, according to the company.
FTSE Russell said the June 2026 reconstitution captures up to the 4,000 largest U.S. stocks as of the April 30 rank day and ranks them by total market capitalization. LSEG also said about $12.2 trillion in investor assets are benchmarked to, or invested in products based on, the Russell U.S. indexes.
Hyperfine develops the Swoop Portable MR Imaging System, a portable ultra-low-field MRI system for brain imaging. FDA records list Swoop under 510(k) K221393 as a radiology device, with a substantially equivalent decision dated June 10, 2022.
Company:Hyperfine
Hyperfine coverage
Sources
- 10(k) Premarket Notification K221393, Swoop Portable MR Imaging System. Regulatory filing
About the author
RadiologySignal.com writersEditorial Team
Radiology Signal Staff covers developments across medical imaging, radiology AI, imaging informatics, clinical research, and radiology business. The team monitors primary sources, peer-reviewed studies, company announcements, society updates, and healthcare industry news to deliver concise reporting for imaging professionals.
